A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage — The SAS Study

Ardalan Zolnourian(Southampton Hospital), Diederik Bulters(Addenbrooke's Hospital), Stephen Franklin(Evgen Pharma (United Kingdom)), D. Howat(Evgen Pharma (United Kingdom)), Ian Galea(University Hospital Southampton NHS Foundation Trust), Patrick Garland(University of Southampton), Mukul Arora(University Hospital Southampton NHS Foundation Trust), Christopher Uff(Queen Mary University of London), Jonathan R. Rhodes(Edinburgh Royal Infirmary), Anthony A. Birch(University Hospital Southampton NHS Foundation Trust), Patrick Holton(University Hospital Southampton NHS Foundation Trust)
Translational Stroke Research
July 19, 2024
10.1007/s12975-024-01278-1
Cited by 7

Related Papers

Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study
|The Lancet Psychiatry|2020|1.3k
Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial
|The Lancet|2019|891
Forecasting species range dynamics with process‐explicit models: matching methods to applications
|Ecology Letters|2019|252
Assessment of Autoregulation by Means of Periodic Changes in Blood Pressure
|Stroke|1995|197
Evaluation of Outcomes Among Patients With Traumatic Intracranial Hypertension Treated With Decompressive Craniectomy vs Standard Medical Care at 24 Months
|JAMA Neurology|2022|106